Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Diego Burgos-Santamaría,Olga P Nyssen,Antonio Gasbarrini,Dino Vaira,Ángeles Pérez-Aisa,Luís Rodrigo,Rinaldo Pellicano,Alma Keco-Huerga,Manuel Pabón-Carrasco,Manuel Castro-Fernandez,Doron Boltin,Jesus Barrio,Perminder Phull,Juozas Kupcinskas,Laimas Jonaitis,Inmaculada Ortiz-Polo,Bojan Tepes,Alfredo J Lucendo,José María Huguet,Miguel Areia,Natasa Brglez Jurecic,Maja Denkovski,Luís Bujanda,June Ramos-San Román,Antonio Cuadrado-Lavín,Judith Gomez-Camarero,Manuel Alfonso Jiménez Moreno,Angel Lanas,Samuel Jesús Martinez-Dominguez,Enrique Alfaro,Ricardo Marcos-Pinto,Vladimir Milivojevic,Theodore Rokkas,Marcis Leja,Sinead Smith,Ante Tonkić,György Miklós Buzás,Michael Doulberis,Marino Venerito,Frode Lerang,Dmitry S Bordin,Vincent Lamy,Lisette G Capelle,Wojciech Marlicz,Daniela Dobru,Oleksiy Gridnyev,Ignasi Puig,Francis Mégraud,Colm O'Morain,Javier P Gisbert
DOI: https://doi.org/10.1136/gutjnl-2022-328232
IF: 24.5
2023-05-06
Gut
Abstract:Objective To evaluate the use, effectiveness and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe. Design International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociación Española de Gastroenterología-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis. Results Overall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed >90% of cases. Overall effectiveness remained <90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p<0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted ≥14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%. Conclusion Empirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update. Trial registration number NCT02328131.
gastroenterology & hepatology